Haemotoxicity of chloramphenicol succinate in the CD-1 mouse and Wistar Hanover rat

Human and Experimental Toxicology

Volumn 18, Issue 9, 1999, Pages 566-576

  Turton, J A ^a   Yallop, D ^a   Andrews, C M ^b   Fagg, R ^b   York, M ^b   Williams, T C ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Aplastic anaemia; Chloramphenicol succinate; Haemotoxicity; Mouse; Rat

Indexed keywords

CHLORAMPHENICOL HEMISUCCINATE; HEMOGLOBIN;

ANEMIA; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BLOOD CHEMISTRY; BLOOD TOXICITY; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; LEUKOCYTE COUNT; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RETICULOCYTE; THROMBOCYTE COUNT;

ANEMIA, APLASTIC; ANIMALS; APOPTOSIS; BLOOD CELL COUNT; BONE MARROW; CHLORAMPHENICOL; CLINICAL CHEMISTRY TESTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC TESTS; HEMATOPOIETIC STEM CELLS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

ANIMALIA;

EID: 0032872940     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032799678845098     Document Type: Article

References (45)

1. Volini IF et al. Hemopoietic changes during administration of chloramphenicol (chloromycetin). Journal of the American Medical Association 1950; 142: 1333-1355.
2. Reynolds JEF, Martindale. The Extra Pharmacopoeia, 29th Edition. The Pharmaceutical Press, London, 1989.
3. Chaplin S. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol-part II. Adverse Drug Reactions and Acute Poisoning Reviews 1986; 3: 181-196.
4. Young NS, Alter BP. Aplastic Anemia: Acquired and Inherited. WB Saunders, Philadelphia, 1994.
5. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Chloramphenicol. Volume 50. pp. 169-193. IARC, Lyon, 1990.
6. FAO/WHO Expert Committee on Food Additives. Chloramphenicol. In: Toxicological Evaluation of Certain Veterinary Drug Residues in Food (WHO Food Additives Series 23). pp.1-71. World Health Organisation, Geneva, 1988.
7. Krakoff IH, Karnofsky DA, Burchenal JH. Effects of large doses of chloramphenicol on human subjects. The New England Journal of Medicine 1955; 253: 7-10.
8. Scott JL, Finegold SM, Belkin GA, Lawrence JS. A controlled double blind study of the haematologic toxicity of chloramphenicol. The New England Journal of Medicine 1965; 272: 1137-1142.
9. Rich ML, Ritterhoff RJ, Hoffmann RJ. A fatal case of aplastic anaemia following chloramphenicol (chloromycetin) therapy. Annals of Internal Medicine 1950; 33: 1459-1467.
10. Welch H, Lewis CN, Kerlan I. Blood dyscrasias. A nationwide survey. Antibiotics and Chemotherapy 1954; 4: 607-623.
11. Wallestein RO et al. Statewide study of chloramphenicol therapy and fatal aplastic anaemia. Journal of the American Medical Association 1969; 208: 2045-2050.
12. Yunis AA, Bloomberg GR. Chloramphenicol toxicity, clinical features and pathogenesis. Progress in Haematology 1964; 4: 138-159.
13. Brauer MJ, Dameshek W. Hypoplastic anaemia and myeloblastic leukemia following chloramphenicol therapy. Report of three cases. The New England Journal of Medicine 1967; 277: 1003-1005.
14. 1 mice using flow cytometry. Comparative Haematology International 1993; 3: 102-115.
15. 1 mice treated with busulphan. Comparative Haematology International 1998; 8: 125-136.
16. 1 mouse. Human and Experimental Toxicology 1998; 17: 8-17.
17. Morley A, Blake J. An animal model of chronic hypoplastic marrow failure. I. Late marrow failure after busulphan. Blood 1974; 44: 49-56.
18. Morley A, Trainor K, Remes J. Residual marrow damage: possible explanation for idiosyncrasy to chloramphenicol. British Journal of Haematology 1976; 32: 525-531.
19. Morley AA, Trainor KJ, Seshadri RS. Chronic hypoplastic marrow failure and residual injury. Blood Cells 1978; 4: 253-266.
20. Yallop D et al. Chloramphenicol is haemotoxic at high dose levels in the mouse but not in the rat. Human and Experimental Toxicology 1998; 17: 57.
21. Spurling NW, Burton LK, Pilling T. Canine factor-VII deficiency: experience with a modified Thrombotest method in distinguishing between phenotypes. Research in Veterinary Science 1974; 16: 228-239.
22. Godsafe PA, Singleton BK. The use of the whole blood Thrombotest time (1/51) as a routine monitor of vitamin K-dependent blood coagulation factor levels in the rat. Comparative Haematology International 1992; 2: 51-55.
23. Pazdernik TL, Corbett MD. Role of chloramphenicol reduction products in aplastic anaemia. Pharmacology 1980; 20: 87-94.
24. Robin E et al. Induction of lymphomas in mice by busulphan and chloramphenicol. Cancer Research 1981; 41: 3478-3482.
25. Bhoopalam N et al. Busulphan and chloramphenicol induced T cell lymphoma: cell surface characteristics and functional properties. Clinical and Experimental Immunology 1986; 64: 646-655.
26. Hara H, Kohsaki M, Noguchi K, Nagai K. Effect of chloramphenicol on colony formation from erythrocytic precursors. American Journal of Haematology 1978; 5: 123-130.
27. Vácha J, Pospišil M, Velovský V. The toxic effect of chloramphenicol on erythropoiesis in X-irradiated mice. Chemotherapy 1981; 27: 131-138.
28. Firkin FC, Sumner MA, Bradley TR. The influence of chloramphenicol on the bone marrow haemopoietic stem cell compartment. Experimental Haematology 1974; 2: 264-268.
29. Gruhzit OM, Fisken RA, Reutner TF, Martino E. Chloramphenicol (chloromycetin), an antibiotic. Pharmacological and pathological studies in animals. Journal of Clinical Investigation 1949; 28: 943-952.
30. Fritz H, Hess R. The effect of chloramphenicol on the prenatal development of rats, mice and rabbits. Toxicology and Applied Pharmacology 1971; 19: 667-674.
31. Rosenbach LM, Caviles AP, Mitus WJ. Chloramphenicol toxicity: reversible vacuolization of erythroid cells. The New England Journal of Medicine 1960; 263: 274-278.
32. Saidi P, Wallerstein RO, Aggeler PM. Effect of chloramphenicol on erythropoiesis. Journal of Laboratory and Clinical Medicine 1961; 57: 247-256.
33. Scott JL, Finegold SM, Belkin GA, Lawrence JS. A controlled double-blind study of the hematologic toxicity of chloramphenicol. The New England Journal of Medicine 1965; 272: 1137-1142.
34. Schrober R, Kosek JC, Wolf PL. Chloramphenicol-induced vacuoles. Their ultrastructure in bone marrow pronormoblasts and immature myeloid cells. Archives of Pathology 1972; 94: 298-302.
35. Morris TH. Antibiotic therapeutics in laboratory animals. Laboratory Animals 1995; 29: 16-36.
36. Alison PM, Mummah Schendel LL, Kindberg CC. Effects of vitamin K-deficient diet and antibiotics in normal human volunteers. Journal of Clinical Medicine 1987; 110: 180-188.
37. Reddy J, Bailey RR. Vitamin K deficiency developing in patients with renal failure treated with cephalosporin antibiotics. New Zealand Medical Journal 1980; 92: 378-379.
38. Bengmark S, Goransson G, Soucas E. Defects in hemostasis produced by antibiotics. An in vivo study in the rat. European Surgical Research 1981; 13: 290-298.
39. Smith RM et al. Chloromycetin: biological studies. Journal of Bacteriology 1948; 55: 425-448.
40. Philpott NJ et al. Increased apoptosis in aplastic anaemia bone marrow progenitor cells: Possible pathophysiologic significance. Experimental Haematology 1995; 23: 1642-1648.
41. Holt DE et al. The myelotoxicity of chloramphenicol: in vitro and in vivo studies: I. In vitro effects on cells in culture. Human and Experimental Toxicology 1997; 16: 570-576.
42. Mandal B, Hazra N, Maity CR. Metabolic and enzymatic changes in rats following high doses of tetracycline, chloramphenicol and trimethoprim. Annals of the National Academy of Medical Sciences (India) 1982; 18: 146-156.
43. Rubin D, Weisberger AS, Botti RE, Storaasli JB. Changes in iron metabolism in early chloramphenicol toxicity. Journal of Clinical Investigation 1958; 37: 1286-1292.
44. Suhrland LG, Weisberger AS. Chloramphenicol toxicity; in liver and renal disease. Archives of Internal Medicine 1963; 112: 747-754.
45. Yunis A. Drug-induced bone marrow injury. Advances in Internal Medicine 1969; 15: 357-376.